An Observation about the FDA briefing document
I have one observation about the FDA Pfizer document. In the FDA briefing document on Pfizer vax for kids 5 to 11, the strongest argument in favor of authorization is this one: [Paragraph separation mine] FDA conducted a quantitative benefit-risk analysis to evaluate predicted numbers of symptomatic COVID-19 cases, hospitalizations, ICU admissions, and deaths that would be prevented per million fully vaccinated children 5-11 years of age over a 6-month period, as compared with predicted numbers of vaccine-associated excess myocarditis cases, hospitalizations, ICU admissions and deaths per million fully vaccinated children 5-11 years of age…
Read more
4 years ago · 9 likes · 6 comments · Vinay Prasad
